SEVEN AND EIGHT BIOPHARMACEUTICALS

Seven and Eight Biopharmaceuticals Inc. is a biopharmaceutical company devoted to the discovery and development of new targeted cancer immunotherapies. We are the leaders in dendritic cell reprogramming therapies, working with TLR7/8 agonists to activate the innate immunity and generate adaptive immune responses... Seven and Eight Biopharmaceuticals Inc. is an experienced biopharmaceutical company committed to discovering and developing new and innovative immunotherapies. Researchers and Clinicians at Seven and Eight Biopharma are using advanced techniques to develop novel therapies to activate the immune system against cancer. Ongoing clinical trials are studying these novel therapies in patients with cancer... Established in 2012, Seven and Eight Biopharma was founded with exclusive insight from Dr. Yong-Jun Liu. A proprietary pipeline of novel cancer drug candidates activating TLR7 and TLR8 were produced, along with a proprietary drug conjugation technology platform.

Also known as: Seven, Seven and Eight Biopharmaceuticals Inc

Primary location: Edison United States